Project Grant R01AA030774

Award Date 8/1/24
Completion Date 7/31/28
Dollars Obligated $582K
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40507, USA
Similar Awards
The Project Grant award, titled "CHARACTERIZING BRAIN-PERIPHERY CORTISOL DYSREGULATION IN AUD", is funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The award, totaling $701,135.00, will be executed by Yale University over a project period from September 1, 2024, to August 31, 2027. The key products and services to be delivered under this grant include: 1) Fully characterizing the availability of the...
This $275,171.12 Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), supports a clinical neuroscience study to understand the relationship between chronic stress and alcohol use disorder (AUD). The study, led by researchers at the University of California, Los Angeles (UCLA), will objectively assess chronic stress and examine dynamic functional connectivity within the brain's stress coping system using...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $545,282 to investigate neural mechanisms associated with cognitive reappraisal and alcohol cue reactivity during early abstinence in individuals with alcohol use disorder (AUD). The project aims to 1) determine how neural mechanisms related to reappraisal and alcohol cue-reactivity change across early abstinence...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) program, will fund a longitudinal study on social cognition deficits and their impact on recovery outcomes for individuals with Alcohol Use Disorder (AUD). The $351,413 award will support a 5-year research project at the University of Florida to: Assess emotion processing abilities and related cognitive/affective functions in recently abstinent...
This federal Project Grant award of $366,406 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support the development of a novel human laboratory paradigm for screening alcohol use disorder (AUD) medications. The project aims to create two versions of an "ability to resist drinking" model that can assess the efficacy of AUD medications in achieving key FDA-approved endpoints, such as abstinence and reduced...
This $711,808 Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program supports a 5-year research initiative at Yale University. The research aims to leverage advances in machine learning and computational modeling to develop and validate whole-brain biomarkers for stress, and test whether dynamic engagement of these stress networks can predict individual differences in drinking behavior and...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, provides $594,784 to Yale University to conduct a postmortem, multi-omic study of brains from 341 subjects to investigate the molecular pathology of alcohol use disorder (AUD). The overarching goal is to identify novel transcriptomic and epigenetic changes in brain regions associated with AUD, which could lead to the discovery of...
This federal Project Grant award, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to evaluate the neural correlates of social and affective reward gained from alcohol consumption in social contexts. The $194,616 award supports a study that will examine how alcohol dose and social familiarity factors influence the brain's reward and social processing mechanisms during a music-listening task performed by participant...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will provide $497,581.76 to Yale University to conduct research on avoidance learning and pain circuit dysfunction in alcohol use disorders (AUD). The key objectives of this 3-year project are to: 1) characterize dysfunctions in brain circuits supporting pain reactivity and cognitive control during avoidance learning in AUD patients compared to social...
This $388,800 federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will support Dr. Srivastava's research on the neural mechanisms of anxiety during early and protracted abstinence in alcohol use disorder (AUD). The project aims to investigate how alterations in anxiety circuitry involving the bed nucleus of the stria terminalis (BNST), anterior insula (AI), and dorsolateral prefrontal cortex (DLPFC) may...

This federal Project Grant award, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), provides $581,869 to The University of Kentucky Research Foundation to conduct a human neuroscience study on the effects of selective glucocorticoid receptor antagonism in alcohol use disorder (AUD).

The study aims to translate preclinical findings on the role of glucocorticoid receptors in alcohol reward, withdrawal, and stress-induced relapse to human participants. Researchers will examine behavioral, neuroendocrinological, and physiological responses to experimentally induced stress and alcohol administration after maintenance on varying doses of the selective glucocorticoid receptor antagonist PT150. The project also includes an exploratory component to assess potential sex differences and predictors of treatment response. Ultimately, the research could provide the impetus for further clinical development of PT150 as an adjunct therapy for AUD.

Generated 6/10/25, 2:52 AM